What changes will be made to the medical insurance policy for selumetinib in 2025?

Selumetinib , as a targeted MEK inhibitor, has been launched in the domestic market and has become an effective option for the treatment of plexiform neurofibromas (PN) through combination with other drugs. With the continuous optimization of the national medical insurance policy, selumetinib has been gradually included in the medical insurance catalog, bringing good news to the majority of patients.

In the past few years, the medical insurance policy for selumetinib has undergone some changes, especially in the promotion and use of the drug in the domestic market. Initially, the price of selumetinib was relatively high. Due to the import fees and production costs of its original drug, its price in the market remained high, far exceeding the ability of many patients to pay. In order to benefit more patients, the national medical insurance policy regulates the inclusion of selumetinib and provides some specific usage guidelines.

First of all, selumetinib’s medical insurance policy mainly targets patients with symptomatic and inoperable plexiform neurofibromatosis (PN) neurofibromatosis type I (NF1), especially those children aged 3 years and above. This regulation further clarifies the scope of use of selumetinib and ensures that the drug can be given priority to special groups who really need treatment. This is undoubtedly an expansion of treatment opportunities for those pediatric patients facing serious diseases.

In addition, selumetinib’s medical insurance pricing strategy has also been adjusted. Although the price of its original drug is still high, with the intensification of market competition, the emergence of generic drugs and the continuous maturation of related technologies, the price of selumetinib has been gradually declining. Especially after being included in medical insurance, the patient's personal burden has been greatly reduced. This allows more patients to choose to use this drug under the guidance of doctors, thereby achieving better therapeutic effects.

Reference materials:https://www.koselugo.com